RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Effects of Odanacatib in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 19
SP 21
OP 21
DO 10.1177/155989771219018
UL http://mdc.sagepub.com/content/12/19/21.1.abstract
AB Odanacatib is a selective, potent, and reversible cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This article discusses results of A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK0822) in Postmenopausal Women Previously Treated with Alendronate. The trial found odanacatib to be safe and effective for increasing bone mineral density in postmenopausal women previously treated with alendronate.